- Home
- CUE vs IMMX Comparison
CUE vs IMMX Comparison
Compare CUE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- IMMX
- Stock Information
- Founded
- CUE 2014
- IMMX 2014
- Country
- CUE United States
- IMMX United States
- Employees
- CUE N/A
- IMMX N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CUE Health Care
- IMMX Health Care
- Exchange
- CUE Nasdaq
- IMMX Nasdaq
- Market Cap
- CUE 59.5M
- IMMX 65.5M
- IPO Year
- CUE 2018
- IMMX 2021
- Fundamental
- Price
- CUE $0.83
- IMMX $2.19
- Analyst Decision
- CUE Strong Buy
- IMMX Strong Buy
- Analyst Count
- CUE 2
- IMMX 1
- Target Price
- CUE $3.00
- IMMX $7.00
- AVG Volume (30 Days)
- CUE 118.2K
- IMMX 250.2K
- Earning Date
- CUE 08-12-2025
- IMMX 08-08-2025
- Dividend Yield
- CUE N/A
- IMMX N/A
- EPS Growth
- CUE N/A
- IMMX N/A
- EPS
- CUE N/A
- IMMX N/A
- Revenue
- CUE $8,286,000.00
- IMMX N/A
- Revenue This Year
- CUE N/A
- IMMX N/A
- Revenue Next Year
- CUE $23.84
- IMMX N/A
- P/E Ratio
- CUE N/A
- IMMX N/A
- Revenue Growth
- CUE N/A
- IMMX N/A
- 52 Week Low
- CUE $0.45
- IMMX $1.26
- 52 Week High
- CUE $1.99
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- CUE 53.58
- IMMX 39.38
- Support Level
- CUE $0.77
- IMMX $2.11
- Resistance Level
- CUE $0.84
- IMMX $2.39
- Average True Range (ATR)
- CUE 0.06
- IMMX 0.21
- MACD
- CUE -0.00
- IMMX -0.03
- Stochastic Oscillator
- CUE 71.90
- IMMX 9.52
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.